```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1644pnh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Sep 29   The Philippines Inventory of Chemicals and Chemical
                   Substances (PICCS) has been added to CHEMLIST
 NEWS  3  Oct 27   New Extraction Code PAX now available in Derwent
                   Files
 NEWS  4  Oct 27   SET ABBREVIATIONS and SET PLURALS extended in
                   Derwent World Patents Index files
 NEWS  5  Oct 27   Patent Assignee Code Dictionary now available
                   in Derwent Patent Files
 NEWS  6  Oct 27   Plasdoc Key Serials Dictionary and Echoing added to
                   Derwent Subscriber Files WPIDS and WPIX
 NEWS  7  Nov 29   Derwent announces further increase in updates for DWPI
 NEWS  8  Dec  5   French Multi-Disciplinary Database PASCAL Now on STN
 NEWS  9  Dec  5   Trademarks on STN - New DEMAS and EUMAS Files
 NEWS 10  Dec 15   2001 STN Pricing
 NEWS 11  Dec 17   Merged CEABA-VTB for chemical engineering and
                   biotechnology
 NEWS 12  Dec 17   Corrosion Abstracts on STN
 NEWS 13  Dec 17   SYNTHLINE from Prous Science now available on STN
 NEWS 14  Dec 17   The CA Lexicon available in the CAPLUS and CA files
 NEWS 15  Jan 05   AIDSLINE is being removed from STN
 NEWS 16  Feb 06   Engineering Information Encompass files have new names
 NEWS 17  Feb 16   TOXLINE no longer being updated

 NEWS EXPRESS  FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!
               (WINDOWS) NOW AVAILABLE
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:00:37 ON 17 APR 2001

=> file medline embase biosis scisearch caplus

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 12:00:54 ON 17 APR 2001

FILE 'EMBASE' ENTERED AT 12:00:54 ON 17 APR 2001

FILE 'BIOSIS' ENTERED AT 12:00:54 ON 17 APR 2001

FILE 'SCISEARCH' ENTERED AT 12:00:54 ON 17 APR 2001

FILE 'CAPLUS' ENTERED AT 12:00:54 ON 17 APR 2001

=> s diagnostic

L1 1290572 DIAGNOSTIC

=> s l1 and schizophrenia

L2 12154 L1 AND SCHIZOPHRENIA

=> s l2 and platelet

L3 136 L2 AND PLATELET

=> s l3 and isolectic point

L4 0 L3 AND ISOLECTIC POINT

=> s l3 and pI

L5 1 L3 AND PI

=> d l5 all

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
AN 1999:390463 CAPLUS
DN 131:16115
TI Skin test for **schizophrenia**
IN Shinitzky, Meir; Deckmann, Michael
PA Yeda Research and Development Co. Ltd., Israel
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N033-68
CC 9-16 (Biochemical Methods)
Section cross-reference(s): 14
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 9930163 A1 19990617 WO 1998-IL592 19981207
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9914457 A1 19990628 AU 1999-14457 19981207
EP 1036333 A1 20000920 EP 1998-958394 19981207
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, SE, IE
BR 9813402 A 20001010 BR 1998-13402 19981207
PRAI IL 1997-122490 19971207
WO 1998-I
L592 19981207
AB A **diagnostic** method for assaying **schizophrenia** in a subject is provided wherein a prepn. comprising **platelet** derived proteins or fractions thereof having a **pI** above about 6.5 is injected into a subject and the occurrence of delayed type hypersensitivity (DTH) reaction at the site of the injection is detd. A pos. DTH reaction indicates that the tested subject has a high likelihood of being schizophrenic. The protein prepn. used in the **diagnostic** method is also provided as well as a method for its prepn. and a kit for use in the diagnosis of **schizophrenia** using the above method.
ST **schizophrenia** diagnosis skin test
IT Blood
Diagnosis
Platelet (blood)
Schizophrenia
Skin
(skin test for **schizophrenia**)
IT Proteins, general, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(skin test for **schizophrenia**)
RE.CNT 2
RE
(1) Burbaea, G; Zk Nevropatol Psikhiatr im S S Korsakova 1986, V86(1), P193 CAPLUS
(2) Yeda Research and Development Company Ltd; WO 9713152 A 1997 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 12:00:37 ON 17 APR 2001)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 12:00:54 ON 17 APR 2001
L1 1290572 S DIAGNOSTIC
L2 12154 S L1 AND SCHIZOPHRENIA
L3 136 S L2 AND PLATELET
L4 0 S L3 AND ISOLECTIC POINT
L5 1 S L3 AND PI

=> dup remove l3

```
PROCESSING COMPLETED FOR L3
L6           85 DUP REMOVE L3 (51 DUPLICATES REMOVED)

=> d l6 1


L6   ANSWER 1 OF 85  CAPLUS  COPYRIGHT 2001 ACS
AN   2000:241564  CAPLUS
DN   132:288780
TI   Methods of identifying inverse agonists of the serotonin 2a receptor,
     therapeutic and diagnostic methods, and test kit
IN   Weiner, David; Brann, Mark R.
PA   Acadia Pharmaceuticals Inc., USA
SO   PCT Int. Appl., 42 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.   DATE
     ---------------    ----  --------       ---------------   --------
PI   WO 2000020636      A1    20000413       WO 1999-US21439   19991007
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9963912          A1    20000426       AU 1999-63912     19991007
PRAI US 1998-103317     19981007
     US 1999-413626     19991006
     WO 1999-US21439    19991007
RE.CNT  7
RE
(1) Eggerickx, D; BIOCHEMICAL JOURNAL 1995, V309, P837 CAPLUS
(3) Herrick, D; WO 9838217 A 1998 CAPLUS
(4) Inst Of Psychiatry; WO 9617081 A 1996 CAPLUS
(6) Shenker, A; NATURE 1993, V365, P652 CAPLUS
(7) Smith, J; WO 9952927 A 1999 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 12:00:37 ON 17 APR 2001)

     FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 12:00:54 ON
     17 APR 2001
L1      1290572 S DIAGNOSTIC
L2        12154 S L1 AND SCHIZOPHRENIA
L3          136 S L2 AND PLATELET
L4            0 S L3 AND ISOLECTIC POINT
L5            1 S L3 AND PI
L6           85 DUP REMOVE L3 (51 DUPLICATES REMOVED)
```

=> s l3 and protein

L7 8 L3 AND PROTEIN

=> dup remove l7

PROCESSING COMPLETED FOR L7
L8 5 DUP REMOVE L7 (3 DUPLICATES REMOVED)

=> d l8 1-5 all

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 2000:227858 CAPLUS
DN 132:260666
TI Identifying agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use
IN Dykens, James A.; Miller, Scott W.; Ghosh, Soumitra S.; Davis, Robert E.
PA Mitokor, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N033-50
ICS G01N033-68; A61K031-00; C07C279-26
CC 1-1 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000019200	A1	20000406	WO 1999-US22261	19990924
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9961628	A1	20000417	AU 1999-61628	19990924
PRAI	US 1998-161172		19980925		
	WO 1999-US22261		19990924		

AB Methods are provided for identifying agents that affect mitochondrial functions and cell death. Such agents are useful for treating diseases assocd. with mitochondrial dysfunction and in methods of identifying a risk or presence of such diseases. In particular, the invention relates to the loss of mitochondrial membrane potential (.DELTA..PSI.m) during mitochondrial permeability transition (MPT) and further provides a measurable rate loss function, changes in which are useful e.g. for detecting agents that affect one or more mitochondrial functions, for detecting mitochondrial diseases, and for studying mol. components of mitochondria that regulate MPT.
ST mitochondria permeability transition pore therapeutic identification; diagnosis mitochondrial disease permeability transition pore; cell death mitochondrial permeability therapeutic identification; membrane potential mitochondria **diagnostic** therapeutic identification
IT Transport **proteins**

RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(ADP/ATP carrier; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Cyclophilins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(D; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Apolipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E, genotype; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Nervous system
(Huntington's chorea; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Brain, disease
(MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes); identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Muscle, disease
(MERRF (myoclonic epilepsy assocd. with ragged-red muscle fibers); identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Animal cell line
(SH-SY5Y, cybrid cell produced with; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Annexins
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(V, FITC conjugates; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Anion channel
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(VDAC (voltage-dependent anion-selective channel); identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Neurotransmitters
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(amino acid; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Diabetes mellitus
(and mitochondrial diabetes and deafness; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(bcl-2, Bcl-2 gene family-encoded polypeptide; identification of agents
that alter mitochondrial permeability transition pores and cell death
for **diagnostic** and therapeutic use)
IT Membrane potential
(biol.; identification of agents that alter mitochondrial permeability
transition pores and cell death for **diagnostic** and
therapeutic use)
IT Transport **proteins**
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(calcium-transporting, mitochondrial calcium uniporter; identification
of agents that alter mitochondrial permeability transition pores and
cell death for **diagnostic** and therapeutic use)
IT **Platelet** (blood)
(cybrid cell produced with; identification of agents that alter
mitochondrial permeability transition pores and cell death for
diagnostic and therapeutic use)
IT Animal cell
(cybrid cell; identification of agents that alter mitochondrial
permeability transition pores and cell death for **diagnostic**
and therapeutic use)
IT Muscle, disease
(degeneration; identification of agents that alter mitochondrial
permeability transition pores and cell death for **diagnostic**
and therapeutic use)
IT Mitochondria
(diseases; identification of agents that alter mitochondrial
permeability transition pores and cell death for **diagnostic**
and therapeutic use)
IT Nervous system
(dystonia; identification of agents that alter mitochondrial
permeability transition pores and cell death for **diagnostic**
and therapeutic use)
IT Pathogen
(eukaryotic; identification of agents that alter mitochondrial
permeability transition pores and cell death for **diagnostic**
and therapeutic use)
IT Indicators
(for inner mitochondrial membrane potential; identification of agents
that alter mitochondrial permeability transition pores and cell death
for **diagnostic** and therapeutic use)
IT Eye, disease
(hereditary optic atrophy; identification of agents that alter
mitochondrial permeability transition pores and cell death for
diagnostic and therapeutic use)
IT Cell proliferation
(hyperproliferative disease; identification of agents that alter
mitochondrial permeability transition pores and cell death for
diagnostic and therapeutic use)
IT Affinity labeling
Alzheimer's disease
Anti-Alzheimer's agents
Antidiabetic agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Apoptosis

Brain, disease
Cell death
Diagnosis
Drug delivery systems
Drug screening
Electron transport system, biological
Fluorometry
Genotypes
Insect (Insecta)
Ionophores
Lepidoptera
Mitochondria
Necrosis
Neoplasm
Nucleic acid library
Parkinson's disease
Plant (Embryophyta)
Psoriasis
Schizophrenia
(identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT DNA
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Cell proliferation
(inhibitors; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Mitochondria
(inner membrane; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Membrane, biological
(inner mitochondrial; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Biological transport
(intracellular, phosphatidylserine; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Acidosis
(lactic acidosis; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Time-of-flight mass spectrometry
(laser-induced photodesorption; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Deafness
(mitochondrial diabetes and deafness; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Amino acids, biological studies

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(neurotransmitter; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Parasite
(of human; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Eukaryote (Eukaryotae)
(pathogen; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Benzodiazepine receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(peripheral; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Biological transport
(permeation; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Laser ionization mass spectrometry
(photodesorption, matrix-assisted; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Laser desorption mass spectrometry
(photoionization, matrix-assisted; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Laser desorption mass spectrometry
(time-of-flight; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Antibodies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(to cytochrome c; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT Phosphatidylserines
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(translocation; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT 145037-81-6, Rhod 2
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(Rhod 2; identification of agents that alter mitochondrial permeability
transition pores and cell death for **diagnostic** and therapeutic use)

IT 51-83-2, Carbachol 56-86-0, L-Glutamic acid, biological studies 6384-92-5, N-Methyl-D-aspartic acid 11076-19-0, Bongkrekic acid 11103-72-3, Ruthenium red 17754-44-8, Atractyloside 56092-81-0, Ionomycin 67526-95-8, Thapsigargin 79217-60-0, Cyclosporin 169332-61-0 182374-54-5D, derivs. 201608-13-1 217174-04-4
RL: BAC (Biological activity or effector, except adverse); BIOL

(Biological study)
(identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT 9007-43-6, Cytochrome c, biological studies 122191-40-6, Caspase 1 169592-56-7, Caspase 3 186322-81-6, Caspase
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT 102-02-3, 1-Phenylbiguanide
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT 7440-70-2, Calcium, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT 2156-29-8 3520-43-2, JC-1 18198-39-5, Tetraphenylphosphonium 27072-45-3D, Fluorescein isothiocyanate, annexin V conjugates 30827-04-4, Rhodamine B hexyl ester 53213-82-4, DiOC6(3) 62669-70-9, Rhodamine 123 115532-49-5 137993-41-0, Rhodamine 800 139626-15-6, Tetramethylrhodamine ethyl ester
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT 9001-15-4, Creatine kinase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(mitochondrial intermembrane; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

IT 9001-51-8, Hexokinase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(mitochondrial-assocd.; identification of agents that alter mitochondrial permeability transition pores and cell death for **diagnostic** and therapeutic use)

RE.CNT 4
RE
(1) Beal, M; Biochimica et Biophysica Acta 1998, V1366(1-2), P211 CAPLUS
(2) Diamond, J; GB 1410925 A 1975 CAPLUS
(3) Friberg, H; Journal of Neuroscience 1998, V18(14), P5151 CAPLUS
(4) Hirsch, T; Cell Biology and Toxicology 1998, V4(2), P141

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1999:390463 CAPLUS
DN 131:16115
TI Skin test for **schizophrenia**
IN Shinitzky, Meir; Deckmann, Michael
PA Yeda Research and Development Co. Ltd., Israel
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DT Patent
LA English
IC ICM G01N033-68
CC 9-16 (Biochemical Methods)
Section cross-reference(s): 14
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9930163	A1	19990617	WO 1998-IL592	19981207
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9914457	A1	19990628	AU 1999-14457	19981207
	EP 1036333	A1	20000920	EP 1998-958394	19981207
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, SE, IE				
	BR 9813402	A	20001010	BR 1998-13402	19981207

PRAI IL 1997-122490 19971207
WO 1998-I
L592 19981207

AB A **diagnostic** method for assaying **schizophrenia** in a subject is provided wherein a prepn. comprising **platelet** derived **proteins** or fractions thereof having a pI above about 6.5 is injected into a subject and the occurrence of delayed type hypersensitivity (DTH) reaction at the site of the injection is detd. A pos. DTH reaction indicates that the tested subject has a high likelihood of being schizophrenic. The **protein** prepn. used in the **diagnostic** method is also provided as well as a method for its prepn. and a kit for use in the diagnosis of **schizophrenia** using the above method.

ST **schizophrenia** diagnosis skin test

IT Blood
Diagnosis
Platelet (blood)
Schizophrenia
Skin
(skin test for **schizophrenia**)

IT **Proteins**, general, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(skin test for **schizophrenia**)

RE.CNT 2
RE
(1) Burbaea, G; Zk Nevropatol Psikhiatr im S S Korsakova 1986, V86(1), P193 CAPLUS
(2) Yeda Research and Development Company Ltd; WO 9713152 A 1997 CAPLUS

L8 ANSWER 3 OF 5 MEDLINE DUPLICATE 1
AN 1999177784 MEDLINE
DN 99177784
TI [Brain isoforms of creatine kinase in health and mental diseases: Alzheimer's disease and **schizophrenia**].
Mozgovaia izoforma kreatinfosfokinazy v norme i pri psikhicheskikh zabolevaniiakh (bolezn' Al'tsgemera, shizofreniia).

AU Burbaeva GSh; Savushkina O K; Dmitriev A D
SO VESTNIK ROSSIISKOI AKADEMII MEDITSINSKIKH NAUK, (1999) (1) 20-4. Ref: 39
Journal code: BL9. ISSN: 0869-6047.
CY RUSSIA: Russian Federation
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Russian
EM 199906
EW 19990601
AB The paper analyzes the authors' own findings and the data available in the literature on the intensity, site, and possible causes of impairment of the creatine-creatine phosphate system of brain energy metabolism in mental diseases, such as Alzheimer's disease (AD) and **schizophrenia**. Examining the level of cytosolic BB creatine kinase in postmortem AD and schizophrenic's brain structures showed a significant decrease in BB creatine kinase as compared with the similar control brain structures. There was the maximum decline in AD cases. It was considerable as compared with both the control and schizophrenic groups ($p < 0.01$). The decrement was revealed by various techniques, including the determination of activity, immunological responsiveness and the analysis of two-dimensional **protein** maps. Immunocytochemical investigation indicated a decrease in responses to BB creatine kinase, mainly in astrocytes. The reduction in cytosolic BB creatine kinase levels is not a result of age, postmortem delay, or psychotic therapy. The causes of lower BB creatine kinase levels in the cell cytosol of the postmortem brain in mental pathology are discussed. The decrement in cytosolic BB creatine kinase in AD and **schizophrenia** occurs not only in the brain, but also in the peripheral tissues which contain BB creatine kinase. In all cases, it is greater in AD than in **schizophrenia**. Using immunosorbents with monoclonal antibodies to M-creatine kinase and to B-creatine kinase subunits makes it possible detect BB-creatine kinase in the extracts of human peripheral lymphocytes and **platelets**. A study of whether there is a relationship between the clinical data of mental patients and the level of BB creatine kinase in their blood elements is assumed to be useful in evaluating BB creatine kinase as a prognostic/**diagnostic** marker of mental diseases.
CT Check Tags: Comparative Study; Human
Alzheimer Disease: DI, diagnosis
*Alzheimer Disease: EN, enzymology
Biological Markers
*Brain: EN, enzymology
*Creatine Kinase Isoenzymes: ME, metabolism
Diagnosis, Differential
English Abstract
Schizophrenia: DI, diagnosis
***Schizophrenia: EN, enzymology**
CN EC 2.7.3.- (Creatine Kinase Isoenzymes); 0 (Biological Markers)

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1998:568669 CAPLUS
DN 129:185107
TI Cloning and cDNA sequence of a human G-**protein** coupled receptor

(HTADX50) and its **diagnostic** and therapeutic uses
IN Bergsma, Derk J.; Ellis, Catherine E.
PA Smithkline Beecham Corp., USA
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C12N015-12
ICS C07K014-705; A61K038-17; C12Q001-68; C12N015-11; C07K016-28; A61K048-00; G01N033-74
CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 6, 13, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 859053	A1	19980819	EP 1997-309253	19971118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 5910430	A	19990608	US 1997-788750	19970124
JP 10304887	A2	19981117	JP 1998-51208	19980126
PRAI US 1997-788750		19970124		

AB HTADX50 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. The cDNA encoding human HTADX50 was first identified from a human activated T-cell cDNA library, and contains an open reading frame encoding a **protein** of 330 amino acids with a deduced mol. wt. of 37.1 kDa. HTADX50 has about 28% identity in 293 amino acid residues with the thrombin receptor, and is also homologous to **platelet**-activating factor receptor and the ATP receptor; the cDNA has about 60.1% identity in 972 nucleotide residues with human B-cell receptor cDNA and is also homologous to interleukin-8 receptor cDNA. Also disclosed are methods for utilizing HTADX50 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurol. disorders, including anxiety, **schizophrenia**, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and **diagnostic** assays for such conditions.
ST G **protein** coupled receptor HTADX50 human; sequence receptor HTADX50 cDNA human
IT G **protein**-coupled receptors
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(HTADX50; cloning and cDNA sequence of a human G-**protein** coupled receptor (HTADX50) and its **diagnostic** and therapeutic uses)
IT Diagnosis
Drug screening
Drugs
Molecular cloning

(cloning and cDNA sequence of a human G-**protein** coupled receptor (HTADX50) and its **diagnostic** and therapeutic uses)

IT Antibodies
Primers (nucleic acid)
Probes (nucleic acid)
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cloning and cDNA sequence of a human G-**protein** coupled receptor (HTADX50) and its **diagnostic** and therapeutic uses)

IT Mutation
(detn. of mutations in diseases; cloning and cDNA sequence of a human G-**protein** coupled receptor (HTADX50) and its **diagnostic** and therapeutic uses)

IT cDNA sequences
(for human G-**protein** coupled receptor HTADX50)

IT **Protein** sequences
(of human G-**protein** coupled receptor HTADX50)

IT 199397-48-3P
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; cloning and cDNA sequence of a human G-**protein** coupled receptor (HTADX50) and its **diagnostic** and therapeutic uses)

IT 211806-14-3P
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; cloning and cDNA sequence of a human G-**protein** coupled receptor (HTADX50) and its **diagnostic** and therapeutic uses)

L8 ANSWER 5 OF 5 MEDLINE DUPLICATE 2
AN 88204208 MEDLINE
DN 88204208
TI Sialic acid in **platelets** of schizophrenic patients.
AU Sirota P; Bessler H; Allalouf D; Djaldetti M; Levinsky H
CS Yehuda Abrabanel Mental Health Center, Bat Yam, Israel.
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY, (1988) 12 (1) 103-7.
Journal code: Q45. ISSN: 0278-5846.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198808
AB 1. Nerve cell membrane sialic acid is involved in the activity of nervous tissue by its capacity to bind Ca ions and positively charged biogenic amines. 2. Blood **platelets** may serve as a model for amine-storing neurons. 3. The purpose of the present study was to determine the sialic acid content of **platelets** of schizophrenic patients in view of reports showing a reduced serotonin uptake by their **platelets**. 4. To this end **platelets** were isolated from the blood of 26 schizophrenic patients (13 males and 13 females) of various **diagnostic** subtypes and from 21 healthy subjects, and sialic acid was determined after hydrolysis at 80 degrees for 1 h in 0.1 NHCl. 5. The results showed significantly lower contents of sialic acid in the patients as compared to controls calculated both per 10(8) cells and per mg **protein** (18% and 25% lower, respectively) and appear to

be in line with the reduced serotonin uptake in their cells in **schizophrenia**. 6. There were no appreciable differences between sexes and between the various subtypes of this disease.

CT Check Tags: Female; Human; Male
Adult
***Blood Platelets: ME, metabolism**
***Schizophrenia: BL, blood**
Serotonin: BL, blood
*Sialic Acids: BL, blood

RN 131-48-6 (N-Acetylneuraminic Acid); 50-67-9 (Serotonin)
CN 0 (Sialic Acids)

=> d his

(FILE 'HOME' ENTERED AT 12:00:37 ON 17 APR 2001)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 12:00:54 ON 17 APR 2001

L1 1290572 S DIAGNOSTIC
L2 12154 S L1 AND SCHIZOPHRENIA
L3 136 S L2 AND PLATELET
L4 0 S L3 AND ISOLECTIC POINT
L5 1 S L3 AND PI
L6 85 DUP REMOVE L3 (51 DUPLICATES REMOVED)
L7 8 S L3 AND PROTEIN
L8 5 DUP REMOVE L7 (3 DUPLICATES REMOVED)

=> s l6 and DHT

L9 0 L6 AND DHT

=> s l6 and delayed type hypersensitivity reaction

L10 0 L6 AND DELAYED TYPE HYPERSENSITIVITY REACTION

=> s l6 and DTH

L11 1 L6 AND DTH

=> d l11

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
AN 1999:390463 CAPLUS
DN 131:16115
TI Skin test for **schizophrenia**
IN Shinitzky, Meir; Deckmann, Michael
PA Yeda Research and Development Co. Ltd., Israel
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9930163	A1	19990617	WO 1998-IL592	19981207

```
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
             MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
             TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9914457        A1   19990628       AU 1999-14457    19981207
     EP 1036333        A1   20000920       EP 1998-958394   19981207
         R:  AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, SE, IE
     BR 9813402        A    20001010       BR 1998-13402    19981207
PRAI IL 1997-122490   19971207
     WO 1998-I
L592    19981207
RE.CNT  2
RE
(1) Burbaea, G; Zk Nevropatol Psikhiatr im S S Korsakova 1986, V86(1), P193
    CAPLUS
(2) Yeda Research and Development Company Ltd; WO 9713152 A 1997 CAPLUS


=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   39.71      39.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -2.35      -2.35

STN INTERNATIONAL LOGOFF AT 12:08:18 ON 17 APR 2001
```